Featured Article
Parkinson Disease Prevalence Severely Underestimated: Parkinson's Foundation Prevalence Project
The Parkinson's Foundation Prevalence Project estimates that within the next 2 years, 930,000 people in the United States will be living with the condition; that number is anticipated to rise to 1.2 million by 2030.
Latest
Do β2‐Adrenoreceptor Medications Affect Parkinson Disease Risk?
In order to determine the risk of PD associated with various β2‐adrenoreceptor drugs, the study authors assessed United States Medicare beneficiary data from 2009.
Reverse Nocturnal BP Dipping Identifies Cardiovascular Dysautonomia in Parkinson Disease
A greater proportion of patients with dysautonomia had supine hypertension compared with patients without dysautonomia.
FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid
Based on the data, the FDA has concluded that the drug's benefit continues to outweigh its risks for patients with hallucinations and delusions associated with Parkinson's disease psychosis.
Loss of Function Variants in LRRK1 and LRRK2 Not Linked to Parkinson Disease
Kinase inhibition or allele-specific targeting of mutant LRRK2 may still be a meaningful target for therapeutic development.
FDA Approves Tiglutik for the Treatment of Amyotrophic Lateral Sclerosis
The FDA approval was supported by data from bioavailability studies comparing riluzole tablets and Tiglutik oral suspension.
Sensor Array May Detect De Novo Parkinson's Disease in Breath
A sensor array has the potential to identify de novo Parkinson's disease (PD) patients with high sensitivity, specificity, and accuracy values.
Repetitive TMS for Parkinson Disease Depression Non-Superior to SSRI Therapy
The studies that included neurocognitive measures demonstrated no significant difference between the use of rTMS and sham-rTMS.
Treadmill Walking Associated With Improved Ambulation in Rett Syndrome
No differences were observed between overground and treadmill walking with regard to stride and stance time.
Action Tremor May Have Central Origin in Motor Neuron Disease
The inability to compare patients with vs without tremor as well as the inclusion of patients attending a single center, which may reduce the generalizability of the findings.
Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
Rasagiline was associated with a significant effect on survival within 6 months of treatment in an exploratory analysis.
Neurology Advisor Articles
- Deep Brain Stimulation Improves Parkinson Disease in Older Adults
- Optimizing Treatment for Patients With Chronic Sciatica: Gabapentin vs Pregabalin
- Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis
- Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions
- A New Look at Demyelination and White Matter Density in Multiple Sclerosis